{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:38:13Z","timestamp":1792165093542,"version":"4.4.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Prader\u2013Willi syndrome (PWS) is characterized by lack of appetite control and hyperphagia, leading to obesity. Pharmacological options for weight management are needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine whether liraglutide treatment for weight management is superior to placebo\/no treatment in pediatric individuals with PWS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a multicenter, 52-week, placebo-controlled trial with a 16-week double-blinded period. Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage &amp;lt;2) with PWS and obesity were included. Patients were randomized 2:1 to liraglutide 3.0\u2005mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped. Liraglutide was continued for 52 weeks. All patients followed a structured diet and exercise program throughout the trial. The coprimary endpoints were change in body mass index (BMI) standard deviation score (SDS) from baseline to 16 and 52 weeks. Secondary endpoints included other weight-related parameters, hyperphagia, and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Change in BMI SDS from baseline to weeks 16 and 52 was not significantly different between treatments in adolescents (estimated treatment difference: \u22120.07 at week 16 and \u22120.14 at week 52) and children (\u22120.06 and \u22120.07, respectively). Changes in other weight-related parameters between treatments were not significant. At week 52, hyperphagia total and drive scores were lower in adolescents treated with liraglutide vs no treatment. The most common adverse events with liraglutide were gastrointestinal disorders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although the coprimary endpoints were not met, changes in hyperphagia total and drive scores in adolescents warrant further studies on liraglutide in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac549","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T12:28:24Z","timestamp":1664627304000},"page":"4-12","source":"Crossref","is-referenced-by-count":67,"title":["Liraglutide for Weight Management in Children and Adolescents With Prader\u2013Willi Syndrome and Obesity"],"prefix":"10.1210","volume":"108","author":[{"given":"Gwena\u00eblle","family":"Diene","sequence":"first","affiliation":[{"name":"French National Reference Center for Prader\u2013Willi Syndrome, Children's Hospital, University Hospital Center of Toulouse , 31059 Toulouse Cedex 9, Toulouse , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moris","family":"Angulo","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology , NYU Langone Hospital, NY 11501 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M","family":"Hale","sequence":"additional","affiliation":[{"name":"Diabetes Clinical Development and Research , Novo Nordisk Inc., Plainsboro, NJ 08536 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie H","family":"Jepsen","sequence":"additional","affiliation":[{"name":"Precision Medicine , Novo Nordisk A\/S, 2860 S\u00f8borg , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L","family":"Hofman","sequence":"additional","affiliation":[{"name":"Liggins Institute, University of Auckland , Aukland 1023 , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Hokken-Koelega","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center\/Sophia Children's Hospital , 3015 CN Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chethana","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Service Center , Novo Nordisk India, Bangalore, Karnataka 560066 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Turan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology and Diabetes, Marmara University School of Medicine , 34854 Maltepe\/\u0130stanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-7862","authenticated-orcid":false,"given":"Ma\u00efth\u00e9","family":"Tauber","sequence":"additional","affiliation":[{"name":"French National Reference Center for Prader\u2013Willi Syndrome, Children's Hospital, University Hospital Center of Toulouse , 31059 Toulouse Cedex 9, Toulouse , France"},{"name":"Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 \u2013 CNRS UMR5051, University of Toulouse III , 31024 Toulouse Cedex 3, Toulouse , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"issue":"4","key":"2022121716472906400_dgac549-B1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1573396315666190716120925","article-title":"Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update","volume":"15","author":"Butler","year":"2019","journal-title":"Curr Pediatr Rev"},{"key":"2022121716472906400_dgac549-B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-33536-0","volume-title":"Management of Prader-Willi Syndrome","author":"Butler","year":"2006","edition":"3rd ed"},{"key":"2022121716472906400_dgac549-B3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neubiorev.2015.10.003","article-title":"Prader-Willi syndrome: from genetics to behaviour, with special focus on appetite treatments","volume":"59","author":"Griggs","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"2022121716472906400_dgac549-B4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1542\/peds.2010-2820","article-title":"Clinical report\u2014health supervision for children with Prader-Willi syndrome","volume":"127","author":"McCandless","year":"2011","journal-title":"Pediatrics"},{"issue":"4","key":"2022121716472906400_dgac549-B5","first-page":"269","article-title":"Metabolic syndrome in children with Prader-Willi syndrome: the effect of obesity","volume":"21","author":"Brambilla","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2022121716472906400_dgac549-B6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2147\/DMSO.S141352","article-title":"Obesity management in Prader-Willi syndrome: current perspectives","volume":"11","author":"Crin\u00f2","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6","key":"2022121716472906400_dgac549-B7","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"issue":"10077","key":"2022121716472906400_dgac549-B8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"(1)","key":"2022121716472906400_dgac549-B9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022121716472906400_dgac549-B10","author":"European Medicines Agency","year":"2019"},{"key":"2022121716472906400_dgac549-B11","author":"US Food and Drug Administration","year":"2014"},{"issue":"22","key":"2022121716472906400_dgac549-B12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"2022121716472906400_dgac549-B13","doi-asserted-by":"publisher","author":"Diene","year":"2022","DOI":"10.5281\/zenodo.7143491"},{"issue":"(7244)","key":"2022121716472906400_dgac549-B14","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/bmj.320.7244.1240","article-title":"Establishing a standard definition for child overweight and obesity worldwide: international survey","volume":"320","author":"Cole","year":"2000","journal-title":"BMJ"},{"issue":"7","key":"2022121716472906400_dgac549-B15","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/oby.2007.216","article-title":"Assessment of hyperphagia in Prader-Willi syndrome","volume":"15","author":"Dykens","year":"2007","journal-title":"Obesity (Silver Spring)"},{"issue":"(Suppl 1)","key":"2022121716472906400_dgac549-B16","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2337\/dc18-S006","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes. 2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"issue":"Suppl 27","key":"2022121716472906400_dgac549-B17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/pedi.12698","article-title":"ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes","volume":"19","author":"Abraham","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"(1)","key":"2022121716472906400_dgac549-B18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/dc16-2215","article-title":"Glucose concentrations of less than 3.0 mmol\/L (54 mg\/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"40","author":"International Hypoglycaemia Study Group","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"2022121716472906400_dgac549-B19","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.2337\/dc13-2575","article-title":"Use of GLP-1 receptor agonists in Prader-Willi syndrome: report of six cases","volume":"37","author":"Fintini","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"2022121716472906400_dgac549-B20","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"issue":"5","key":"2022121716472906400_dgac549-B21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1530\/EJE-12-0997","article-title":"GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases","volume":"168","author":"Zoicas","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2022121716472906400_dgac549-B22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/dom.14224","article-title":"A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity","volume":"23","author":"Roth","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2022121716472906400_dgac549-B23","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/dom.14366","article-title":"MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity","volume":"23","author":"Perez","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2022121716472906400_dgac549-B24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41366-021-01043-6","article-title":"Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist","volume":"46","author":"Shoemaker","year":"2022","journal-title":"Int J Obes (Lond)"},{"issue":"8","key":"2022121716472906400_dgac549-B25","doi-asserted-by":"crossref","first-page":"E1314","DOI":"10.1210\/jc.2011-0038","article-title":"Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome","volume":"96","author":"Sze","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2022121716472906400_dgac549-B26","doi-asserted-by":"crossref","first-page":"e0248739","DOI":"10.1371\/journal.pone.0248739","article-title":"Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome","volume":"16","author":"Kayadjanian","year":"2021","journal-title":"PLoS One"},{"issue":"(5)","key":"2022121716472906400_dgac549-B27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/ajmg.a.36405","article-title":"Hypoglycemia in Prader-Willi syndrome","volume":"164A","author":"Harrington","year":"2014","journal-title":"Am J Med Genet A"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac549\/46446187\/dgac549.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/1\/4\/48076705\/dgac549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/1\/4\/48076705\/dgac549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:48:07Z","timestamp":1671295687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/1\/4\/6736895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,1]]},"published-print":{"date-parts":[[2022,12,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac549","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,10,1]]}}}